You are here:  Home  >  Central Coast Health Watch  >  Current Article

FDA approves biosimilar of Amgen’s Neulasta

By   /   Monday, June 4th, 2018  /   Comments Off on FDA approves biosimilar of Amgen’s Neulasta

    Print       Email
The U.S. Food and Drug Administration handed approval to Pennsylvania-based pharmaceutical developer Mylan on June 4 for its biosimilar of Amgen’s Neulasta. Neulasta sales slipped 2 percent in 2017, but still brought the regional biotech giant more than $4.5 billion, or around a fifth of its revenue and second only to blockbuster rheumatoid arthritis drug…


    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

You might also like...

Henry Dubroff

Dubroff: U.S. Bank’s big buy revives long-simmering rivalry with Wells Fargo

Read More →